Article
Biochemistry & Molecular Biology
William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang
Summary: Immunotherapy in soft tissue sarcoma has become a popular and promising therapeutic strategy, with immune checkpoint inhibitors showing effectiveness in certain subtypes. Combination therapies have also shown enhanced response rates.
Article
Oncology
Sarah Watson, Benjamin Verret, Stanislas Ropert, Julien Adam, Rastislav Bahleda, Sylvain Briand, Andrea Cavalcanti, Ali N. Chamseddine, Charles Court, Elie Fadel, Matthieu Faron, Leila Haddag-Miliani, Clemence Henon, Cecile Le Pechoux, Antonin Levy, Olaf Mercier, Carine Ngo, Charles Honore, Axel Le Cesne, Olivier Mir
Summary: The activity of single-agent gemcitabine in advanced angiosarcoma was evaluated in this study. The results showed that gemcitabine had clinically meaningful activity, especially in cardiac angiosarcoma and patients who had received prior treatments.
Article
Oncology
Do Weon Lee, Han-Soo Kim, Ilkyu Han
Summary: The study found that actual 5-year survival in stage III soft tissue sarcoma patients is associated with tumor size, histological grade, and ASA score. Nevertheless, the majority of long-term survivors still exhibit factors of poor prognosis.
Review
Pharmacology & Pharmacy
Tomoki Nakamura, Akihiro Sudo
Summary: Trabectedin is a safe and effective therapeutic option for patients with advanced STS. While it may be effective as first-line treatment in selected patients, doxorubicin remains the preferred choice for locally advanced or metastatic STS.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Vinod Ravi, Aparna Subramaniam, Jing Zheng, Behrang Amini, Van A. Trinh, Jocelyn Joseph, Robert G. Mennel, Andrew J. Bishop, Erich M. Sturgis, Ryan P. Goepfert, Sudha Yalamanchili, Gilberto Botello, Bettzy Stephen, Sarina A. Piha-Paul, Anisha B. Patel, Alexander J. Lazar, Anthony P. Conley, Robert S. Benjamin, Shreyaskumar R. Patel, Phillip A. Futreal, Neeta Somaiah, Aung Naing
Summary: This retrospective study assessed the clinical activity of pembrolizumab monotherapy in patients with angiosarcoma. The results showed durable clinical activity of pembrolizumab in angiosarcoma, indicating a high probability of success for checkpoint inhibition as monotherapy or combination therapy.
Article
Oncology
Amy C. Degnim, Brittany L. Siontis, Safia K. Ahmed, Tanya L. Hoskin, Tina J. Hieken, James W. Jakub, Christian L. Baum, Courtney Day, Sarah E. Schrup, Lauren Smith, Jodi M. Carter, Tiffany M. Sae Kho, Katrina N. Glazebrook, Aparna Vijayasekaran, Scott H. Okuno, Ivy A. Petersen
Summary: This study evaluated the impact of trimodality treatment compared to monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment. The study found that trimodality therapy demonstrated a higher rate of pathological complete response and improved 5-year recurrence-free survival, but had more surgical complications and toxic effects.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Tom Wei-Wu Chen, Ruru Chun-Ju Chiang, Alex Le Cesne, Yu-Chun Hsieh, Antoine Italiano, Ya-Wen Yang, Nicolas Penel, Wen-Chung Lee, Emmanuelle Bompas, Thibaud Valentin, Philippe Anract, Nelly Firmin, Florence Duffaud, Ann-Lii Cheng, Francoise Ducimetiere, K. Arnold Chan, Jean-Yves Blay
Summary: The study found significant differences in the incidence and clinical characteristics of soft tissue sarcoma (STS) among different geographic and ethnic populations, suggesting that geographic and ethnic factors may play a crucial role in the pathogenesis of STS.
Article
Biochemistry & Molecular Biology
Timur I. Fetisov, Sofya A. Khazanova, Polina A. Shtompel, Ekaterina S. Trapeznikova, Victoria Y. Zinovieva, Valeria I. Marshall, Anastasia A. Lovenger, Dmitriy V. Rogozhin, Tararykova A. Anastasia, Beniamin Yu. Bokhyan, Gennady A. Belitsky, Marianna G. Yakubovskaya, Kirill I. Kirsanov
Summary: Treatment of highly malignant soft tissue sarcomas (STSs) involves multicomponent therapy, but personalized selection of chemotherapy is lacking. In this study, in vitro chemosensitivity/resistance assays (CSRAs) were used to predict STS chemoresistance. Results showed that certain cancer histotypes had higher resistance to specific drugs and combinations, and the CSRAs were correlated with clinical responses and survival outcomes. CSRAs can assist physicians in avoiding ineffective treatments and aid researchers in developing new STS drugs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Xin-Yu Ke, Ye Chen, Valarie Yu-Yan Tham, Ruby Yu-Tong Lin, Pushkar Dakle, Kassoum Nacro, Mark Edward Puhaindran, Peter Houghton, Angela Pang, Victor Kwanmin Lee, Ling-Wen Ding, Sigal Gery, Jeffrey Hill, Leilei Chen, Liang Xu, H. Phillip Koeffler
Summary: Depletion of MNK1/2 suppresses growth of soft tissue sarcoma cells, and a novel MNK inhibitor ETC-168 shows significant antiproliferative efficacy. Combination of ETC-168 with MCL1 inhibitor exerts synergistic antiproliferative activity against STS cells. This study highlights the potential clinical translation of MNK inhibitors for the treatment of soft tissue sarcoma.
Article
Biochemistry & Molecular Biology
Mauro Loi, Giulia Salvatore, Michele Aquilano, Daniela Greto, Cinzia Talamonti, Viola Salvestrini, Maria Elena Melica, Marianna Valzano, Giulio Francolini, Mariangela Sottili, Costanza Santini, Carlotta Becherini, Domenico Andrea Campanacci, Monica Mangoni, Lorenzo Livi
Summary: Trabectedin sensitizes STS cells to radiation therapy by reducing cell survival rate, inhibiting invasiveness, altering cell cycle distribution, and increasing γ-H2AX foci formation. However, it does not have a synergistic effect on DNA damage repair, neoangiogenesis, and the immune system.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, Sabin Goktas Aydin, Emrah Eraslan, Muhammed Ali Kaplan, Birol Ocak, Sema Sezgin Goksu, Semra Paydas, Fahri Akgul, Sumeyye Derin, Yakup Ergun, Emre Yekeduz, Cihan Erol, Deniz Tataroglu Ozyukseler, Atike Gokcen Demiray, Mustafa Karaca, Zeynep Gulsum Guc, Serkan Menekse, Havva Yesil Cinkir, Ozge Gumusay, Abdullah Sakin, Ozlem Ozkul, Hacer Demir, Dilek Erdem, Mehmet Besiroglu, Olcun Umit Unal, Ramazan Acar, Lokman Koral, Suleyman Sahin, Teoman Sakalar, Aykut Bahceci, Ahmet Ozveren, Ulug Mutlu Gunaydin, Mehmet Metin Seker, Veli Sunar, Pinar Dal, Mehmet Artac, Serdar Turhal
Summary: This study retrospectively analyzed the medical records of patients with non-adipocytic metastatic soft tissue sarcoma treated with pazopanib in 37 oncology clinics in Turkey. The results showed that pazopanib is effective and well-tolerated in the treatment of this disease, with better outcomes observed when used earlier and in patients with good performance status.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Immunology
Kayla L. Marritt, Karys M. Hildebrand, Kurt N. Hildebrand, Arvind K. Singla, Franz J. Zemp, Douglas J. Mahoney, Frank R. Jirik, Michael J. Monument
Summary: This study assessed the therapeutic response of intratumoral STING activation in an immunologically cold murine model of undifferentiated pleomorphic sarcoma (UPS). The results showed that a single intratumoral injection of the murine STING agonist resulted in durable cure in up to 60% of UPS-bearing mice. In mice with synchronous lung metastases, STING activation within hindlimb tumors also resulted in 50% cure in both anatomic sites.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Alessandra Buja, Massimo Rugge, Matteo Barillaro, Andrea Miatton, Saveria Tropea, Claudia Cozzolino, Manuel Zorzi, Antonella Vecchiato, Paolo Del Fiore, Antonella Brunello, Vincenzo Baldo, Carlo Riccardo Rossi, Simone Mocellin
Summary: This study aimed to compare the pathological and clinical features of retroperitoneal soft-tissue sarcomas (RPS) and non-RPS, and analyze if the hazard ratio for short-term mortality differs between RPS and non-RPS after adjusting for baseline differences. The analysis found that RPS accounted for 22.8% of cases, with different characteristics compared to non-RPS. The retroperitoneum site was an independent prognostic factor associated with worse overall survival in sarcoma patients.
Article
Oncology
Richard F. Riedel, Victoria Chua, Ania Moradkhani, Natalie Krkyan, Amir Ahari, Atsushi Osada, Sant P. Chawla
Summary: An expansion cohort was conducted to explore the activity of NC-6300 (nanoparticle epirubicin) in angiosarcoma. The results showed that NC-6300 was well tolerated and demonstrated promising activity in angiosarcoma patients without prior anthracycline treatment.
Article
Oncology
Rei Kamitani, Kazuhiro Matsumoto, Toshikazu Takeda, Ryuichi Mizuno, Mototsugu Oya
Summary: This study identified prognostic factors for primary renal angiosarcoma (PRA), including metastasis at diagnosis and tumor size exceeding 5 cm. Primary metastatic status and tumor size were independent prognostic factors. Postoperative radiation therapy improved recurrence-free survival (RFS) and disease-specific survival (DSS) in cases of localized PRA with tumors exceeding 5 cm, while systemic therapy improved DSS in cases of metastatic PRA.
Review
Oncology
Jordan Carter, Kevin A. David, Athena Kritharis, Andrew M. Evens
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2020)
Article
Oncology
Chul S. Ha, Michael LeBlanc, Heiko Schoder, Chelsea C. Pinnix, Nancy L. Bartlett, Andrew M. Evens, Eric D. Hsi, Lisa Rimsza, Michael Knopp, Jun Zhang, John P. Leonard, Brad S. Kahl, Hongli Li, Sonali Smith, Louis S. Constine, Jonathan W. Friedberg
LEUKEMIA & LYMPHOMA
(2020)
Article
Hematology
Peter Hokland, Mansi Shah, Kevin David, Andrew Evens, Rebecca Auer, Rifca Ledieu, Stefanie Kreissl, Paul J. Broeckelmann, Peter Borchmann, Anu Korula, Vikram Mathews, Weerapat Owattanapanich, Judith Trotman
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Oncology
Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, Puneet Singh Cheema, Philip A. Dy, Timothy E. O'Brien, Jane N. Winter, Terrence P. Cescon, Julie E. Chang, Brad S. Kahl
CLINICAL CANCER RESEARCH
(2020)
Article
Hematology
Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O'Shea, Leo I. Gordon, Jane N. Winter
Summary: Brief pembrolizumab monotherapy followed by AVD is highly effective and safe for patients with newly diagnosed classical Hodgkin lymphoma, including those with bulky disease.
Editorial Material
Oncology
Andrew M. Evens, Susan K. Parsons
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
Mansi R. Shah, Imraan Jan, Jeremy Johns, Kuldip Singh, Pallavi Kumar, Norma Belarmino, Kara J. Saggiomo, Carolyn Hayes, Kimyatta Washington, Deborah L. Toppmeyer, Bruce G. Haffty, Steven K. Libutti, Andrew M. Evens
Summary: Strict adherence to infection control protocols in outpatient and inpatient oncology units results in minimal environmental contamination with SARS-CoV-2.
Article
Oncology
Adam J. Olszewski, Lasse H. Jakobsen, Graham P. Collins, Kate Cwynarski, Veronika Bachanova, Kristie A. Blum, Kirsten M. Boughan, Mark Bower, Alessia Dalla Pria, Alexey Danilov, Kevin A. David, Catherine Diefenbach, Fredrik Ellin, Narendranath Epperla, Umar Farooq, Tatyana A. Feldman, Alina S. Gerrie, Deepa Jagadeesh, Manali Kamdar, Reem Karmali, Shireen Kassam, Vaishalee P. Kenkre, Nadia Khan, Seo-Hyun Kim, Andreas K. Klein, Izidore S. Lossos, Matthew A. Lunning, Peter Martin, Nicolas Martinez-Calle, Silvia Montoto, Seema Naik, Neil Palmisiano, David Peace, Elizabeth H. Phillips, Tycel J. Phillips, Craig A. Portell, Nishitha Reddy, Anna Santarsieri, Maryam Sarraf Yazdy, Knut B. Smeland, Scott E. Smith, Stephen D. Smith, Suchitra Sundaram, Adam S. Zayac, Xiao-Yin Zhang, Catherine Zhu, Chan Y. Cheah, Tarec C. El-Galaly, Andrew M. Evens
Summary: The BL-IPI provides robust discrimination of survival in adult BL, suitable for use as prognostication and stratification in trials. The high-risk group has suboptimal outcomes with standard therapy and should be considered for innovative treatment approaches.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Hematology
Adam J. Olszewski, Habibe Kurt, Andrew M. Evens
Summary: High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS) is a recently introduced diagnostic category for aggressive B-cell lymphomas. It includes rare and heterogeneous tumors that cannot be classified as other well-defined lymphoma subtypes. Improved molecular diagnostics are needed to improve outcomes and treatment for patients.
Article
Oncology
Angela J. Fong, Andrew M. Evens, Elisa Bandera, Adana A. M. Llanos, Katie A. Devine, Shawna Hudson, Bo Qin, Lisa E. Paddock, Antoinette M. Stroup, Sara Frederick, Carissa Greco, Sharon L. Manne
Summary: This study aimed to characterize the preparedness for survivorship and evaluate the factors associated with it, including sociodemographic, medical, survivorship care transition experiences, practical and psychological factors. The findings revealed that many cancer survivors felt unprepared for survivorship and desired more information about follow-up tests and maintaining good health. Factors such as receiving chemotherapy, limited transition care planning, limited discussion of medical and psychosocial effects, high information needs, and financial hardship predicted low preparedness.
EUROPEAN JOURNAL OF CANCER CARE
(2022)
Article
Hematology
Andrew M. Evens, Justin S. Brandt, Cody J. Peer, Tyler Yin, Dale Schaar, Faheem Farooq, Brett Mozarsky, William D. Figg, Elad Sharon
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Review
Oncology
Pallawi Torka, Eugene Przespolewski, Andrew M. Evens
Summary: The shortage of dacarbazine (DTIC) has caused a crisis in treating classical Hodgkin lymphoma. This review discusses strategies and proposes a treatment algorithm based on fitness and safety for receiving anthracyclines.
JCO ONCOLOGY PRACTICE
(2022)
Article
Oncology
Susan K. Parsons, Kristina S. Yu, Nicholas Liu, Supriya Kumar, Michelle A. Fanale, Katie Holmes, Carlos Flores, Andy Surinach, Darcy R. Flora, Andrew M. Evens
Summary: This study surveyed oncologists treating cHL to understand the treatment decision process, including the impact of PET/CT imaging.
JCO ONCOLOGY PRACTICE
(2023)
Article
Oncology
Andrew M. Evens, Kristina S. Yu, Nicholas Liu, Andy Surinach, Katherine Holmes, Carlos Flores, Michelle A. Fanale, Darcy R. Flora, Susan K. Parsons
Summary: This study aimed to understand the treatment preferences and decision-making of US physicians when it comes to frontline treatment for stage III/IV classic Hodgkin lymphoma (cHL). Results showed that the most common factors considered by physicians when selecting 1L cHL treatments were trial efficacy/safety data and national guidelines. Although treatment selection varied based on patient characteristics, overall survival (OS) was consistently cited as the most important attribute.
Article
Hematology
Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio
Summary: The study found that patients with Burkitt lymphoma who received rituximab treatment had higher survival rates, while factors such as age, ECOG performance status, lactate dehydrogenase levels, and central nervous system involvement could affect patient survival.